kabutan

CHUGAI PHARMA extends gains as U.S. FDA approves Eli Lilly's oral obesity drug Founayo

Thu Apr 2, 2026 9:17 am JST Catalyst

CHUGAI PHARMACEUTICAL CO., LTD. <4519> continued to rise. Eli Lilly announced on the 1st that the U.S. Food and Drug Administration (FDA) has approved its oral obesity treatment drug "Founayo" (generic name: orforglipron). Orforglipron was originally discovered by CHUGAI PHARMA, and Eli Lilly has been advancing its development. In U.S. stock market trading on the 1st, Eli Lilly shares closed up more than 3%, providing support for CHUGAI PHARMA's stock price. CHUGAI PHARMA also announced on the 2nd Japan time that Eli Lilly had disclosed FDA approval for Founayo.

Source: MINKABU PRESS

Related Articles